Wall Street Breakfast Podcast: Wegovy Pill, Novo Surges

Group 1: Novo Nordisk - The US FDA has approved an oral version of Novo Nordisk's Wegovy (semaglutide), marking it as the first GLP-1 oral treatment approved for obesity [3][4] - The approval was based on the OASIS 4 trial, which demonstrated a mean weight loss of 16.6% in adults who were obese or overweight with comorbidities when taking 25 mg of oral semaglutide daily [4] - Novo Nordisk's shares rose approximately 7% in premarket trading following the announcement [4] Group 2: Mercedes-Benz - Mercedes-Benz USA and parent company Daimler AG have agreed to a settlement of $149.6 million over diesel emissions allegations with 48 U.S. states, Puerto Rico, and the District of Columbia [4][5] - The settlement includes a payment of $120 million to the attorneys general, with an additional $29 million payment suspended pending the completion of a consumer relief program [6] Group 3: ByteDance - ByteDance plans to allocate approximately 160 billion yuan (~$22.77 billion) in capital expenditure for 2026, focusing primarily on AI infrastructure development [6][7] - About half of the budget, around 85 billion yuan, is aimed at advanced AI processors, while the remainder will support AI model training and data center expansions, including overseas facilities [7] - ByteDance is considering purchasing 20,000 NVIDIA H200 chips at about $20,000 per unit, which could lead to an increase in capital expenditure if access to more chips is granted [8]